The global serological testing market size was estimated to be USD 5.64 billion in 2023 and is expected to reach at USD 14.5 billion by 2033 with a CAGR of 8.93% during the forecast period 2023-2033. Rising prevalence of infectious diseases such as hepatitis, tuberculosis, & HIV/AIDS, growing incidences of COVID cases across the globe, increasing healthcare expenditure, surge in investment for research & development activities, rising focus on development of analysis kits, presence of supportive government initiatives, growing regulatory approvals for serological tests for a variety of bacterial & viral infections, increasing usage of chemiluminescence immunoassay, surge in antibody tests, rising demand for ELISA, and increasing novel product launches by key players are some of the key factors boosting the market growth.
Increasing novel product launches by key players is predicted to boost the market growth during the forecast period. For instance, in May 2021, Researchers from the Spanish Council for Scientific Research (CSIC) partnered with Madrid Hospitals of La Princesa and La Paz, along with the Spanish biotechnology company Immunostep, to develop and release a novel serological test for COVID-19 antibodies, which is now available in the market.
By Product, Consumables & reagents was the highest revenue-grossing segment in the global serological testing market in 2022 owing to their greater use in tests to produce reliable and repeatable findings, growing demand for consumables & reagents for serological testing, and increasing focus on development of novel products, Additionally, Instruments is predicted to grow at fastest CAGR during the forecast period owing to the growing technological advancements, rising launch of advanced instruments by major market players, and surge in initiatives by key market players. For instance, in May 2020, Abbott revealed the launch of their latest antibody testing blood test, which will be compatible with Abbott's ARCHITECT i1000SR and i2000SR laboratory instruments. Furthermore, the company plans to extend the test to their Alinity i system.
By Technology, ELISA was the highest revenue-grossing segment in the global serological testing market in 2022 owing to growing adoption of ELISA technology globally, rising demand for ELISA test kits by healthcare professionals, and increasing introduction of new ELISA products. For instance, in February 2023, Charles River Laboratories International, Inc. has unveiled its inaugural Enzyme-Linked Immunosorbent Assay (ELISA) Kit, which is designed for detecting and quantifying residual host cell proteins (HCP) in biotherapeutics based on Chinese hamster ovary (CHO) cells. Additionally, NAT is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for molecular diagnostic testing, rising adoption of NAT testing by blood banks & healthcare institutes, and surge in technological advancements.
By Application, Human Immunodeficiency Virus (HIV) was the highest revenue-grossing segment in the global serological testing market in 2022 owing to increasing prevalence of HIV, rising government initiatives to reduce the disease burden, and growing launch novel products. Additionally, Coronavirus (COVID-19) is predicted to grow at fastest CAGR during the forecast period owing to the rising cases of COVID-19, growing demand for serology testing for diagnosis, and increasing launch of new products. For instance, in March 2020, The DPP COVID-19 Serological Point-of-Care Test was made available by Chembio Diagnostic Systems Inc.
By End-User, Blood banks was the highest revenue-grossing segment in the global serological testing market in 2022 owing to surge in number of tests performed before blood or blood products transfusion, increasing adoption of serological tests for blood group typing, growing introduction of advanced products by market players. Additionally, Diagnostic laboratories is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of infectious diseases, increasing demand for diagnostic testing, and rising initiatives by major market players. For instance, in December 2021, Lupin has recently unveiled its diagnostic division, called Lupin Diagnostics, which includes a range of products, including serological tests. This strategic move was made with the aim of offering integrated healthcare solutions to India.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising prevalence of infectious diseases, increasing healthcare infrastructure, growing geriatric population, surge in demand for early diagnosis testing, and increasing new product launches for serological tests. For instance, in March 2020, Becton, Dickinson and Company, in collaboration with BioMedomics, has introduced a rapid serology test designed to detect COVID-19 exposure. The test, created and produced by BioMedomics, is now accessible through BD and is exclusively distributed by Henry Schein, Inc. to healthcare providers across the United States. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of infectious diseases, rising healthcare expenditure, growing research & development activities, surge in usage of chemiluminescence immunoassay, growing demand for ELISA, and rising launch of novel products by key market players. For instance, in August 2020, Transasia Bio-Medicals has introduced the ErbaLisa COVID-19 IgG ELISA test kit in the Indian market.
Increasing novel product launches by key players is predicted to boost the market growth during the forecast period. For instance, in May 2021, Researchers from the Spanish Council for Scientific Research (CSIC) partnered with Madrid Hospitals of La Princesa and La Paz, along with the Spanish biotechnology company Immunostep, to develop and release a novel serological test for COVID-19 antibodies, which is now available in the market.
By Product, Consumables & reagents was the highest revenue-grossing segment in the global serological testing market in 2022 owing to their greater use in tests to produce reliable and repeatable findings, growing demand for consumables & reagents for serological testing, and increasing focus on development of novel products, Additionally, Instruments is predicted to grow at fastest CAGR during the forecast period owing to the growing technological advancements, rising launch of advanced instruments by major market players, and surge in initiatives by key market players. For instance, in May 2020, Abbott revealed the launch of their latest antibody testing blood test, which will be compatible with Abbott's ARCHITECT i1000SR and i2000SR laboratory instruments. Furthermore, the company plans to extend the test to their Alinity i system.
By Technology, ELISA was the highest revenue-grossing segment in the global serological testing market in 2022 owing to growing adoption of ELISA technology globally, rising demand for ELISA test kits by healthcare professionals, and increasing introduction of new ELISA products. For instance, in February 2023, Charles River Laboratories International, Inc. has unveiled its inaugural Enzyme-Linked Immunosorbent Assay (ELISA) Kit, which is designed for detecting and quantifying residual host cell proteins (HCP) in biotherapeutics based on Chinese hamster ovary (CHO) cells. Additionally, NAT is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for molecular diagnostic testing, rising adoption of NAT testing by blood banks & healthcare institutes, and surge in technological advancements.
By Application, Human Immunodeficiency Virus (HIV) was the highest revenue-grossing segment in the global serological testing market in 2022 owing to increasing prevalence of HIV, rising government initiatives to reduce the disease burden, and growing launch novel products. Additionally, Coronavirus (COVID-19) is predicted to grow at fastest CAGR during the forecast period owing to the rising cases of COVID-19, growing demand for serology testing for diagnosis, and increasing launch of new products. For instance, in March 2020, The DPP COVID-19 Serological Point-of-Care Test was made available by Chembio Diagnostic Systems Inc.
By End-User, Blood banks was the highest revenue-grossing segment in the global serological testing market in 2022 owing to surge in number of tests performed before blood or blood products transfusion, increasing adoption of serological tests for blood group typing, growing introduction of advanced products by market players. Additionally, Diagnostic laboratories is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of infectious diseases, increasing demand for diagnostic testing, and rising initiatives by major market players. For instance, in December 2021, Lupin has recently unveiled its diagnostic division, called Lupin Diagnostics, which includes a range of products, including serological tests. This strategic move was made with the aim of offering integrated healthcare solutions to India.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising prevalence of infectious diseases, increasing healthcare infrastructure, growing geriatric population, surge in demand for early diagnosis testing, and increasing new product launches for serological tests. For instance, in March 2020, Becton, Dickinson and Company, in collaboration with BioMedomics, has introduced a rapid serology test designed to detect COVID-19 exposure. The test, created and produced by BioMedomics, is now accessible through BD and is exclusively distributed by Henry Schein, Inc. to healthcare providers across the United States. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of infectious diseases, rising healthcare expenditure, growing research & development activities, surge in usage of chemiluminescence immunoassay, growing demand for ELISA, and rising launch of novel products by key market players. For instance, in August 2020, Transasia Bio-Medicals has introduced the ErbaLisa COVID-19 IgG ELISA test kit in the Indian market.
Segmentation: Serological Testing Market Report 2022 - 2033
Serological Testing Market Analysis & Forecast by Product 2022 - 2033 (Revenue USD Bn)
- Instruments
- Consumables & Reagents
Serological Testing Market Analysis & Forecast by Technology 2022 - 2033 (Revenue USD Bn)
- NAT
- CLIA/CMIA
- ELISA
- Others
Serological Testing Market Analysis & Forecast by Application 2022 - 2033 (Revenue USD Bn)
- Human Immunodeficiency Virus (HIV)
- Coronavirus (COVID-19)
- Hepatitis
- Rotavirus Infections
- Others
Serological Testing Market Analysis & Forecast by End-user 2022 - 2033 (Revenue USD Bn)
- Diagnostic Laboratories
- Blood Banks
- Hospitals
- Other
Serological Testing Market Analysis & Forecast by Region 2022 - 2033 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Serological Testing Market: Product Estimates & Trend Analysis
8. Serological Testing Market: Technology Estimates & Trend Analysis
9. Serological Testing Market: Application Estimates & Trend Analysis
10. Serological Testing Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Serological Testing Market
13. Europe Global Serological Testing Market
14. Asia Pacific Global Serological Testing Market
15. Latin America Global Serological Testing Market
16. MEA Global Serological Testing Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Abbott
- Becton
- Dickinson and Company (BD)
- Cellex Inc.
- Hoffmann La-Roche Ltd
- Randox Laboratories Ltd.
- Thermo Fisher Scientific Inc.
- Eurofins Scientific
- Beckman Coulter Inc.
- BioMedomics Inc.
- Advanced Diagnostics Inc.
- ELITechGroup
- Quest Diagnostics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | August 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 5.64 Billion |
| Forecasted Market Value ( USD | $ 14.5 Billion |
| Compound Annual Growth Rate | 8.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
